# NatureAide User Acceptance Testing (UAT) Sign-Off Document

**Document ID**: NAT-UAT-SGN-001  
**Version**: 1.0.0  
**Effective Date**: October 26, 2026  
**Status**: PENDING UAT EXECUTION & STAKEHOLDER SIGN-OFF  

---

## 1. Executive Summary & Intent

This document records the formal review, evaluation, and acceptance decisions rendered by the designated stakeholder representatives for the NatureAide platform across its four distinct operating tiers:
1. **Community User** (Public Educational & Herbal Catalog)
2. **Scientific Researcher** (12-Stage Botanical Investigation & In-Silico Pipeline)
3. **Health Professional / Independent Reviewer** (Clinical Evaluation, Peer Review & Stage Advancement)
4. **System Administrator** (Institutional Governance, Reviewer Verification, Knowledge Integration & Audit)

Sign-off must reflect the actual results of test cases documented in [NATUREAIDE_UAT_TEST_CASES.md](file:///c:/projects/natureaide/docs/NATUREAIDE_UAT_TEST_CASES.md) and tracked in [NATUREAIDE_UAT_TRACKER.csv](file:///c:/projects/natureaide/docs/NATUREAIDE_UAT_TRACKER.csv).

> [!IMPORTANT]
> No representative or committee member may pre-select or approve a decision prior to the completion and verification of required test cases. All execution statuses must originate from verified human testing sessions.

---

## 2. Overall UAT Execution Metrics Summary

| Metric | Target / SLA | Actual Result |
|---|---|---|
| **Total Defined UAT Test Cases** | 66 Test Cases | [ 66 ] |
| **Total Cases Executed** | >= 95% (>= 63 cases) | [ _To be recorded_ ] |
| **Cases Passed** | - | [ _To be recorded_ ] |
| **Cases Failed** | - | [ _To be recorded_ ] |
| **Cases Not Tested** | 0% at completion | [ 66 initially ] |
| **Overall Pass Rate (%)** | >= 95% required | [ _To be calculated_ ] % |
| **Open CRITICAL Defects** | 0 permitted | [ _To be recorded_ ] |
| **Open HIGH Defects** | 0 permitted | [ _To be recorded_ ] |
| **Open MEDIUM Defects** | Documented workarounds | [ _To be recorded_ ] |
| **Open LOW Defects** | Scheduled maintenance | [ _To be recorded_ ] |

---

## 3. Role-Level Sign-Off Records

Each designated representative must independently review testing outcomes within their domain, verify defect resolution, and select an acceptance recommendation.

---

### A. Community Representative Sign-Off

**Designated Representative**:  
Name: ______________________________  
Organization: _______________________  
Position/Role: ______________________  
Date: ______________________________  

**Domain Test Coverage (Sections B & C — Community & Ask NatureAide)**:  
- **Total Assigned Cases**: 20  
- **Passed**: [ _____ ]  
- **Failed**: [ _____ ]  
- **Not Tested**: [ _____ ]  

**Specific Scope Verification Checklist**:
- [ ] Plant monographs accurately display recognized traditional uses, precautions, and references without confusing technical research jargon.
- [ ] Traditional preparation directions only expose verified, approved domestic methods; no research formulation prototypes are visible.
- [ ] Commercial products catalog only shows registered/published products with official FDA registration numbers.
- [ ] Health screening strictly yields `ELIGIBLE_TO_CONTINUE` or `PROFESSIONAL_GUIDANCE_REQUIRED` and never claims absolute `SAFE` or `UNSAFE`.
- [ ] Ask NatureAide answers educational queries from approved records and reliably responds with grounding boundaries when queries fall outside verified knowledge.
- [ ] Mobile navigation and typography are readable and accessible on 375px, 390px, and 430px screens.

**Recommendation**:
<!-- Select exactly one -->
- [ ] **Accept** (All assigned cases passed; experience is safe, intuitive, and educational)
- [ ] **Accept with Minor Issues** (Minor cosmetic/layout observations noted; zero safety or functional blocks)
- [ ] **Requires Further Testing** (Key workflows incomplete or untested; requires retesting)
- [ ] **Reject for Pilot** (Safety concern, AI fabrication, or critical navigation failure observed)

**Representative Comments / Observations**:  
`[Enter any specific user experience observations, clarity notes, or feedback here]`

**Signature**: ___________________________________________ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Date**: _______________

---

### B. Scientific Researcher Representative Sign-Off

**Designated Representative**:  
Name: ______________________________  
Organization: _______________________  
Position/Role: ______________________  
Date: ______________________________  

**Domain Test Coverage (Sections D & E — Research Dashboard & 12-Stage Journey)**:  
- **Total Assigned Cases**: 23  
- **Passed**: [ _____ ]  
- **Failed**: [ _____ ]  
- **Not Tested**: [ _____ ]  

**Specific Scope Verification Checklist**:
- [ ] 12-Stage research progression accurately reflects real X/12 milestone completion.
- [ ] Plant catalog identity is cleanly distinguished from botanical specimen authentication (Stage 2).
- [ ] Pharmacokinetics (Stage 4) and Molecular Docking (Stage 5) handle engine connectivity states gracefully without fabricating simulation numbers.
- [ ] Formulation Builder (Stage 6) prominently marks entries as `RESEARCH PROTOTYPE` and strictly prevents accidental publication into community preparations.
- [ ] Safety Assessment (Stage 7) registers safety concerns with severity and evidence status without generating unsubstantiated `SAFE`/`UNSAFE` claims.
- [ ] Stage 8 compiles immutable dossiers with clear reviewer preferences; Stage 9 supports revision comparison and resubmission.
- [ ] Stage 10 records real wet-lab test parameters without computational simulation; Stage 11 structures immutable conclusions.
- [ ] Stage 12 produces controlled Knowledge Integration proposals that remain isolated from community data until administrative approval.

**Recommendation**:
<!-- Select exactly one -->
- [ ] **Accept** (Scientific methodology preserved; all stages operable; data immutability intact)
- [ ] **Accept with Minor Issues** (Minor UI or matrix display quirks; scientific records intact)
- [ ] **Requires Further Testing** (Core laboratory or dossier submission workflow blocked)
- [ ] **Reject for Pilot** (Scientific integrity compromised, data lost, or stages improperly unlocked)

**Representative Comments / Observations**:  
`[Enter researcher feedback, scientific observation notes, or laboratory workflow feedback here]`

**Signature**: ___________________________________________ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Date**: _______________

---

### C. Health Professional / Reviewer Representative Sign-Off

**Designated Representative**:  
Name: ______________________________  
Organization: _______________________  
Professional Specialty: ____________  
Date: ______________________________  

**Domain Test Coverage (Sections F & G — Reviewer Dashboard, Workspace & Eligibility)**:  
- **Total Assigned Cases**: 18  
- **Passed**: [ _____ ]  
- **Failed**: [ _____ ]  
- **Not Tested**: [ _____ ]  

**Specific Scope Verification Checklist**:
- [ ] Reviewer dashboard displays active assigned reviews, metrics, and reviewer specialty accurately.
- [ ] Review workspace presents immutable research dossiers with section-by-section navigation.
- [ ] Reviewer can attach severity-categorized comments (`GENERAL_COMMENT`, `CLARIFICATION_NEEDED`, `EVIDENCE_NEEDED`, `CORRECTION_SUGGESTED`, `SAFETY_CONCERN`) to specific dossier lines.
- [ ] Reviewer has strictly read-only access to researcher data and cannot directly edit scientific content.
- [ ] Formal decisions (`REQUEST_REVISION` vs `ACCEPT_FOR_NEXT_STAGE`) properly advance or recycle the review cycle.
- [ ] Decision of `ACCEPT_FOR_NEXT_STAGE` is clearly marked as academic stage progression and is NOT represented as "Medically Approved" or "Safe for Human Use".
- [ ] Unverified, suspended, or disabled reviewers are strictly blocked from rendering official decisions.

**Recommendation**:
<!-- Select exactly one -->
- [ ] **Accept** (Peer review governance robust; reviewer independence strictly upheld)
- [ ] **Accept with Minor Issues** (Minor UI feedback rendering issues; evaluation workflow intact)
- [ ] **Requires Further Testing** (Review submission or revision cycle blocked)
- [ ] **Reject for Pilot** (Reviewer content modification loophole or eligibility bypass identified)

**Representative Comments / Observations**:  
`[Enter clinical evaluation observations, governance feedback, or reviewer experience notes here]`

**Signature**: ___________________________________________ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Date**: _______________

---

### D. System Administrator Sign-Off

**Designated Representative**:  
Name: ______________________________  
Organization: _______________________  
Position/Role: ______________________  
Date: ______________________________  

**Domain Test Coverage (Sections H through P — Administrative Governance, Security, Audit & Provenance)**:  
- **Total Assigned Cases**: 25  
- **Passed**: [ _____ ]  
- **Failed**: [ _____ ]  
- **Not Tested**: [ _____ ]  

**Specific Scope Verification Checklist**:
- [ ] Reviewer verification workflow reliably verifies, suspends, and reactivates reviewers with audit logging.
- [ ] Research oversight provides complete read-only visibility into active projects without permitting admin modification of science.
- [ ] Knowledge Integration lifecycle strictly enforces the transition: `DRAFT` -> `SUBMITTED` -> `CHANGES_REQUESTED` -> `APPROVED` -> `INTEGRATED`, updating community monographs only upon final integration.
- [ ] Knowledge base corrections and restorations always create new version numbers and never overwrite historical rows.
- [ ] User account disabling immediately terminates active sessions and prevents subsequent login while preserving scientific records and audit trails.
- [ ] Central System Audit Workspace provides immutable, read-only event logs with zero delete/clear/edit controls.
- [ ] Cross-role unauthorized route navigation is securely blocked and redirected without data leakage.
- [ ] Bidirectional provenance links community knowledge back to underlying lab validation and research dossiers.

**Recommendation**:
<!-- Select exactly one -->
- [ ] **Accept** (Platform governance, security, and audit immutability fully verified)
- [ ] **Accept with Minor Issues** (Minor filter or sorting defects in admin views; governance controls intact)
- [ ] **Requires Further Testing** (Administrative action fails or security rule fails to enforce)
- [ ] **Reject for Pilot** (Privilege escalation, audit mutability, or unauthorized publication defect observed)

**Representative Comments / Observations**:  
`[Enter institutional governance observations, system remarks, or audit notes here]`

**Signature**: ___________________________________________ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Date**: _______________

---

## 4. Final UAT Decision & Joint Recommendation

Following the execution of all designated UAT test cases and upon thorough review of all role-level sign-offs, the Joint UAT Governance Committee renders the following official verdict for the NatureAide platform:

<!-- Exactly ONE decision must be checked upon completion of UAT -->

```text
[ ] APPROVED FOR CONTROLLED PILOT
    Requirements:
    - 100% of P0 Critical Governance cases executed and passed.
    - Overall test pass rate >= 95%.
    - 0 open CRITICAL defects.
    - 0 open HIGH defects.
    - All four role representatives recommend "Accept" or "Accept with Minor Issues".

[ ] CONDITIONALLY APPROVED FOR CONTROLLED PILOT
    Requirements:
    - 100% of P0 Critical Governance cases executed and passed.
    - 0 open CRITICAL defects.
    - Minor HIGH defects resolved or covered by strict manual protocol workarounds.
    - Overall test pass rate between 90% and 95%.
    - Committee defines explicit mitigation plan and timeline before opening pilot user access.

[ ] NOT APPROVED FOR CONTROLLED PILOT
    Conditions:
    - Any unresolved CRITICAL defect remaining.
    - Any open HIGH defect affecting authentication, reviewer eligibility, AI grounding, or knowledge isolation.
    - Overall test pass rate < 90%.
    - One or more role representatives recommend "Reject for Pilot".
```

---

### Committee Signatures

| Representative Role | Full Name | Signature | Decision Date |
|---|---|---|---|
| **Community Representative** | ___________________________ | ___________________________ | ____________ |
| **Researcher Representative** | ___________________________ | ___________________________ | ____________ |
| **Reviewer Representative** | ___________________________ | ___________________________ | ____________ |
| **System Administrator** | ___________________________ | ___________________________ | ____________ |
| **Lead Quality Engineer** | ___________________________ | ___________________________ | ____________ |
| **Project Sponsor / Director** | ___________________________ | ___________________________ | ____________ |
